Kaitlin Anstett
Overview
Explore the profile of Kaitlin Anstett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeJesus E, Towner Jr W, Gathe J, Cash R, Anstett K
J Acquir Immune Defic Syndr
. 2024 Sep;
97(5):506-513.
PMID: 39250331
Background: Sustained viral suppression in patients with multidrug-resistant (MDR) HIV infection remains difficult; accordingly, agents targeting different steps in the HIV life cycle are needed. Ibalizumab, a humanized immunoglobulin G4...
2.
Anstett K, Brenner B, Mesplede T, Wainberg M
J Virol
. 2018 Sep;
92(20).
PMID: 30258035
No abstract available.
3.
Oliveira M, Ibanescu R, Anstett K, Mesplede T, Routy J, Robbins M, et al.
Retrovirology
. 2018 Aug;
15(1):56.
PMID: 30119633
Background: Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistance profiles are...
4.
Mount H, Revie N, Todd R, Anstett K, Collins C, Costanzo M, et al.
PLoS Genet
. 2018 Apr;
14(4):e1007319.
PMID: 29702647
Invasive fungal infections caused by the pathogen Candida albicans have transitioned from a rare curiosity to a major cause of human mortality. This is in part due to the emergence...
5.
Anstett K, Brenner B, Mesplede T, Wainberg M
J Virol
. 2017 Aug;
91(21).
PMID: 28835492
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in...
6.
Anstett K, Brenner B, Mesplede T, Wainberg M
Retrovirology
. 2017 Jun;
14(1):36.
PMID: 28583191
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretroviral drugs to be approved for treatment and act by inhibiting the essential HIV protein integrase from inserting the viral...
7.
Anstett K, Cutillas V, Fusco R, Mesplede T, Wainberg M
J Antimicrob Chemother
. 2016 Apr;
71(8):2083-8.
PMID: 27084918
Objectives: The E157Q substitution in HIV-1 integrase (IN) is a relatively common natural polymorphism associated with HIV resistance to IN strand transfer inhibitors (INSTIs). Although R263K is the most common...
8.
Liang J, Mesplede T, Oliveira M, Anstett K, Wainberg M
J Virol
. 2015 Aug;
89(22):11269-74.
PMID: 26311878
Unlabelled: The R263K substitution in integrase has been selected in tissue culture with dolutegravir (DTG) and has been reported for several treatment-experienced individuals receiving DTG as part of salvage therapy....
9.
Anstett K, Fusco R, Cutillas V, Mesplede T, Wainberg M
J Virol
. 2015 Aug;
89(20):10482-8.
PMID: 26246578
Unlabelled: We have previously shown that the addition of the raltegravir/elvitegavir (RAL/EVG) primary resistance mutation N155H to the R263K dolutegravir (DTG) resistance mutation partially compensated for the fitness cost imposed...
10.
Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg M
J Virol
. 2015 Feb;
89(8):4681-4.
PMID: 25653436
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue...